DSGN Crosses Above Average Analyst Target
November 14, 2024 at 07:36 AM EST
In recent trading, shares of Design Therapeutics Inc (DSGN) have crossed above the average analyst 12-month target price of $7.00, changing hands for $7.50/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..